SEC Company Response from Aptevo Therapeutics Inc. (APVO) (CIK 0001671584) (APVO) — Feb 11, 2019
Aptevo Therapeutics Inc. (APVO) (CIK 0001671584)
Date: Feb. 11, 2019 · CIK: 0001671584 · Accession: 0001193125-19-034145
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-229115
Letter
Aptevo Therapeutics Inc.
2401 4th Avenue, Suite 1050
Seattle, WA 98121
February 11, 2019
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Todd Schiffman
RE: Aptevo Therapeutics Inc.
Registration Statement on Form S-3
File No. 333-229115
Acceleration Request
Requested Date:
February 13, 2019
Requested Time:
4:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on February 13, 2019, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.
In connection with this request, the Registrant acknowledges that:
•
should the Commission or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
Aptevo Therapeutics Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Aptevo Therapeutics Inc. 2401 4th Avenue, Suite 1050 Seattle, WA 98121 February 11, 2019 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Todd Schiffman RE: Aptevo Therapeutics Inc. Registration Statement on Form S-3 File No. 333-229115 Acceleration Request Requested Date: February 13, 2019 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on February 13, 2019, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable. In connection with this request, the Registrant acknowledges that: • should the Commission or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Very truly yours, Aptevo Therapeutics Inc. /s/ Marvin L. White Marvin L. White President, Chief Executive Officer and Director cc: Jeffrey G. Lamothe, Aptevo Therapeutics Inc. Alan Hambelton, Cooley LLP